NICE Issues Preliminary Recommendations For Basilea’s Toctino(R)

Basilea Pharmaceutica Ltd. (SWISS: BSLN) (PINKSHEETS: BPMUF) announces that the Appraisal Committee of the National Institute for Health and Clinical Excellence (NICE) has developed preliminary positive recommendations with some limitations on the use of Toctino® (alitretinoin) within its licensed indication, as treatment for adults with severe chronic hand eczema that has not responded to potent topical corticosteroids.